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added to a co-culture of myeloid APC and MOG-specific 
T cells. At otherwise undetected concentrations, anti-MOG 
Ab enabled Fc-mediated APC recognition of intact MOG; 
internalized, processed and presented MOG activated naïve 
T cells to differentiate in an encephalitogenic manner. In a 
series of translational experiments, anti-MOG Ab from two 
patients with an acute flare of CNS inflammation likewise 
facilitated detection of human MOG. Jointly, these obser-
vations highlight Ab-mediated opsonization of endogenous 
CNS auto-antigen as a novel disease- and/or relapse-trig-
gering mechanism in CNS demyelinating disorders.
Keywords Auto-antibodies · Opsonization · Myeloid 
antigen-presenting cells · Fc receptor · Experimental 
autoimmune encephalomyelitis · Multiple sclerosis
Introduction
B cells, plasma cells and antibodies (Ab) are increasingly 
recognized as key players in inflammatory central nervous 
system (CNS) demyelinating diseases, such as multiple 
Abstract In the pathogenesis of central nervous system 
(CNS) demyelinating disorders, antigen-specific B cells are 
implicated to act as potent antigen-presenting cells (APC), 
eliciting waves of inflammatory CNS infiltration. Here, 
we provide the first evidence that CNS-reactive antibodies 
(Ab) are similarly capable of initiating an encephalitogenic 
immune response by targeting endogenous CNS antigen 
to otherwise inert myeloid APC. In a transgenic mouse 
model, constitutive production of Ab against myelin oligo-
dendrocyte glycoprotein (MOG) was sufficient to promote 
spontaneous experimental autoimmune encephalomyelitis 
(EAE) in the absence of B cells, when mice endogenously 
contained MOG-recognizing T cells. Adoptive transfer 
studies corroborated that anti-MOG Ab triggered activa-
tion and expansion of peripheral MOG-specific T cells in 
an Fc-dependent manner, subsequently causing EAE. To 
evaluate the underlying mechanism, anti-MOG Ab were 
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sclerosis (MS), neuromyelitis optica (NMO) and related 
disorders. Within the cerebrospinal fluid of the majority of 
MS patients, locally supported plasma cells continuously 
produce oligoclonal immunoglobulin (Ig) [36, 51], which 
remain a hallmark diagnostic finding. B and plasma cells 
are commonly found in MS lesions [41] and Ab deposi-
tion co-localizes with complement activation and ongoing 
demyelination [16]. In NMO, compelling evidence sug-
gests that anti-aquaporin (AQP)-4-Ab selectively target 
astrocytes resulting in subsequent demyelination [29].
B cells constitutively express major histocompatibility 
complex (MHC) class II and act as powerful antigen-pre-
senting cells (APC) when they recognize conformational 
protein antigen via their B cell receptor (BCR) [9]. B cells 
from MS patients reveal signs of chronic activation with 
a differential shift toward antigen-experienced memory 
B cells producing pro-inflammatory cytokines, such as 
interleukin-6 [12] and granulocyte-macrophage colony-
stimulating factor (GM-CSF) [25]. These properties, along 
with the fulminant success of the clinical trials testing anti-
CD20 monoclonal Ab [18, 19], suggest that antigen-experi-
enced B cells may act as potent APC in MS.
A series of recent experimental investigations aimed to 
directly address the role of B cells, plasma cells and Ab in 
development of inflammatory CNS demyelinating disease. 
First, transgenic mice were generated in which B cells rec-
ognize myelin oligodendrocyte protein (MOG) and plasma 
cells constitutively produce high titers of pathogenic anti-
MOG Ab (Th mice); upon active immunization, these mice 
showed a fulminant course of experimental autoimmune 
encephalomyelitis (EAE) with enhanced CNS demyelina-
tion [27]. When Th mice were further crossed with MOG 
T cell receptor (TCR) transgenic mice (2D2 mice) [4], the 
resulting line (Thx2D2) even spontaneously developed 
EAE [3, 21]. A similar observation was reported on the 
SJL/J background, furthermore, demonstrating that trans-
genic T cells can recruit endogenous MOG-specific B cells 
[39]. In an attempt to elucidate which immunological com-
ponents were required for spontaneous EAE development, 
a pivotal recent report demonstrated that myelin-recog-
nizing B and T cells sufficed to trigger EAE development 
in C57BL/6 mice [34], corroborating that auto-reactive B 
cells are an essential APC population in this model.
Notwithstanding these results, we here report on a cru-
cial complementary role of CNS-reactive Ab likely com-
pleting the scenario how initial recognition of auto-antigen 
in development of CNS autoimmune disease can occur. We 
show that traces of CNS antigen are opsonized by myelin-
reactive Ab, making them recognizable for Fc receptor 
carrying myeloid APC. Subsequent to internalization, pro-
cessed myelin antigen is presented to myelin-recognizing 
T cells triggering their expansion and encephalitogenic dif-
ferentiation. We demonstrate that this mechanism indeed 
sparks experimental CNS autoimmunity; first, we show 
that in the absence of B cells, Thx2D2 mice develop spon-
taneous EAE indistinguishable from its course in mice 
containing B cells. Second, and most importantly, adoptive 
transfer of serum from Th mice or of purified anti-MOG Ab 
8.18C5 into naïve 2D2 recipients triggered activation and 
expansion of T cells followed by severe and robust EAE, 
suggesting that the mechanism of Ab-mediated opsoniza-
tion of auto-antigen may indeed contribute to initiation and 
propagation of CNS demyelinating disease.
Materials and methods
Mice
MOG p35-55 TCR transgenic 2D2 mice were kindly pro-
vided by Dr. Kuchroo (Boston, USA). MOG Ig heavy chain 
knockin (Th) mice were kindly provided by Dr. Wekerle 
(Munich, Germany). Fcγ receptor knockout (FcγR−/−) mice 
were kindly provided by Dr. Nimmerjahn (Erlangen, Ger-
many). Wild-type (WT) C57BL/6 mice were purchased from 
Charles River (Sulzfeld, Germany). All murine experiments 
were carried out as approved by the government of Upper 
Bavaria (protocol number 55.2-1-54-2531-67-09) and the 
government of lower Saxony (protocol number 33.9-42502).
B cell depletion
B cell depletion was achieved by weekly intraperitoneal 
(i.p.) injections of 200 µg of murine anti-CD20 or anti-
ragweed isotype control Ab (both provided by Genentech, 
South San Francisco, USA) in 200 µl PBS.
Antigens and EAE induction regiments
Mouse MOG peptide (p) 35-55 (MEVGWYRSPFSRV-
VHLYRNGK) was synthesized by Auspep (Parkville, Aus-
tralia). Murine MOG protein 1-117 (mMOG) and human 
MOG protein (hMOG) were kindly provided by C.C.A. 
Bernard and synthesized, purified and refolded as previ-
ously reported [8]. 8–10 week-old-female Th or WT mice 
were immunized subcutaneously with either a suboptimal 
dose of 35 µg mMOG or an optimal dose of 50 µg mMOG 
in Complete Freund’s Adjuvant (CFA) followed by 200 ng 
of pertussis toxin (Sigma-Aldrich, St. Louis, USA) i.p. at 
the day of immunization and 2 days thereafter. Alterna-
tively, WT mice were immunized with 100 µg MOG p35-
55 in CFA followed by two injections of 300 ng pertussis 
toxin. For spontaneous EAE experiments, Th mice were 
bred with 2D2 mice (Thx2D2). To induce EAE by transfer 
of MOG-specific Ab, a serum preparation containing anti-
MOG Ab or monoclonal Ab clone 8.18C5 were injected 
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into the tail vein of WT or 2D2 recipients. 150 µl Th serum 
or control serum was injected twice a week up to a total 
of five injections; 150 µg 8.18C5 Ab or isotype control 
Ab (clone: MOPC-21, Bio X cell, West Lebanon, USA) 
was injected twice a week up to a total of ten injections. 
In recipients, no immunization or adjuvant treatment was 
added.
Evaluation of EAE
Mice were assessed for clinical signs of EAE as follows: 
0 = no clinical disease, 1 = tail weakness, 2 = hind limb 
weakness, 3 = one paralyzed hind limb, 4 = two paralyzed 
hind limbs, 5 = moribund or dead. To evaluate balance and 
general motor function the elevated beam test was used; 
mice were placed on a raised beam with a maximal height 
of 40–50 cm and a length of 100 cm and the time needed to 
traverse was measured. Mice were evaluated daily starting 
2 weeks prior to the respective treatment.
Intrathecal injection of mMOG
Mice were injected with 40 µg mMOG in 10 µl PBS or 10 µl 
of 10 % Evans blue percutaneously into the cisterna magna 
with a 30-gauge needle in 45° anteflexion of the head.
Generation of anti‑MOG Ab containing serum
Serum containing high titers of pathogenic anti-MOG Ab 
or control serum was obtained from Th mice immunized 
with 100 µg mMOG (Th serum) or from WT mice immu-
nized with 100 µg MOG p35-55 (control serum), respec-
tively. Donor mice were immunized to ensure the maxi-
mum capacity of obtained myelin-specific Ab. 14 days after 
immunization, blood was obtained by puncture of the left 
ventricle; serum was separated by centrifugation, pooled 
for further use and stored at −20 °C.
Preparation and digestion of 8.18C5
Anti-MOG monoclonal Ab clone 8.18C5 was generated by 
hybridoma cells kindly provided by Dr. Linington (Glas-
gow, UK). Hybridoma cells were cultured in complete 
medium (RPMI, 5–10 % fetal calf serum, 50 U/ml peni-
cillin, 50 µg/ml streptomycin, 2 mM l-glutamine, 1 mM 
sodium pyruvate, 0.05 mM β-mercaptoethanol) in large-
scale flasks (Greiner bio-one, Kremsmuenster, Austria) 
and Ab was purified using rProtein A/Protein G Sepharose 
columns (rProtein A/Protein G GraviTrap, GE Healthcare, 
Little Chalfont, UK), according to manufacturer’s recom-
mendations. 8.18C5 IgG was digested by ficin (Pierce 
Mouse IgG1 Fab and F(ab′)2 Preparation Kit, Thermo 
Scientific, Waltham, USA), according to manufacturer’s 
recommendations; integrity and binding capacity of 8.18C5 
Ab and resulting 8.18C5 F(ab′)2 fragments were verified 
by 6 % sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) under non-reducing conditions, 
followed by protein staining with Coomassie brilliant 
blue G250 (Biorad, Munich, Germany) and competitive 
anti-MOG enzyme linked immunosorbent assay (ELISA), 
respectively.
IgG preparation from patients with demyelinating CNS 
inflammation
IgG Ab preparations were isolated by Protein G Sepharose 
4 Fast Flow (GE Healthcare) from plasma exchange fluid 
obtained from two patients with neuromyelitis optica spec-
trum disorders (NMOSD), and plasma from one healthy blood 
donor. One patient was a 62-year-old Caucasian woman with 
past history of relapsing bilateral optic neuritis. The patient 
was admitted because of a severe brainstem relapse that was 
treated with corticosteroids and plasma exchange followed 
by rituximab. The other patient was a 55-year-old Caucasian 
woman with a relapsing disease since the age of 48, who pre-
sented with a severe optic neuritis relapse in January 2016 that 
was treated with corticosteroids and plasma exchange fol-
lowed by rituximab. In both cases, cerebrospinal fluid showed 
no oligoclonal bands, and serum samples were negative for 
anti-AQP-4 Ab but positive for anti-MOG Ab (titer 1:1280, 
patient #1; 1:5120, patient #2) measured by a recombinant 
live cell-based immunofluorescence assay with HEK293 cells 
as previously described [30]. Prior to our in vitro assay, the 
general ability to bind soluble recombinant hMOG was tested 
by ELISA using an anti-MOG Ab positive IgG preparation. 
The healthy blood donor was tested anti-MOG Ab negative, 
and IgG preparation served as negative control. Samples were 
kindly provided by Dr. Reindl (Innsbruck, Austria) and Dr. 
Saiz (Barcelona, Spain). The use of the patient’s material was 
approved by the Ethic Committee of the Hospital Clinic of 
Barcelona, written consent was obtained.
Fc blocking in vivo
To block Fcγ receptors in vivo, mice were injected i.p. 
daily with 100 µg anti-CD16/CD32 Ab (Clone: 2.4G2, 
TONBO bioscience, San Diego, USA) in 100 µl 1xPBS 
starting 2 days prior to further treatment.
Assessment of in vivo proliferation of T cells
In vivo proliferation of T cells was evaluated by i.p injec-
tion of 200 µl Bromdesoxyuridin (BrdU; 10 mg/ml) 24 h 
before flow cytometry evaluation using a BrdU Flow 
kit (BD Pharmingen, San Diego, USA), according to 
manufacturer´s recommendations.
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Generation of bone marrow‑derived myeloid APC
To generate bone marrow-derived macrophages (BMDM), 
bone marrow isolated from hind limbs of WT or FcγR−/− 
mice was cultured at 37 °C for 7 days in medium contain-
ing 30 % conditioned L929 cell supernatant (DMEM, 30 % 
L929 supernatant, 10 % fetal calf serum, 5 % horse serum, 
50 U/ml penicillin, 50 µg/ml streptomycin, 0.05 mM 
β-mercaptoethanol). For bone marrow-derived dendritic 
cell (BMDC) generation, bone marrow was isolated from 
hind limbs of WT mice and cultured for 7 days in complete 
medium (RPMI, 10 % fetal calf serum, 50 U/ml penicil-
lin, 50 µg/ml streptomycin, 2 mM l-glutamine, 1 mM 
sodium pyruvate, 0.05 mM β-mercaptoethanol) containing 
25 ng/ml GM-CSF (Sigma-Aldrich).
Evaluation of antigen uptake by myeloid APC
Adherent BMDM or BMDC were harvested using cell 
scraper, 0.5 × 105 cells/well were plated into 96-well flat-
bottom plates (Sarstedt, Nuembrecht, Germany) and pre-
stimulated with 500 ng/ml lipopolysaccharide (LPS, Sigma-
Aldrich). 24 h thereafter, cells were incubated for 2 h with 
DyLight-405 labeled conformational mMOG (mMOG-
DyLight-405) or ovalbumin (OVA)-FITC (Life Technolo-
gies, Thermo Fisher Scientific) in the presence of 50 µg/ml 
8.18C5 Ab, 8.18C5 F(ab′)2 fragment, anti-OVA Ab (clone: 
TOSG1C6, BioLegend, San Diego, USA) or isotype control 
Ab (clone: MOPC-21). To investigate phagocytosis of con-
formational hMOG, murine BMDM which are known to 
recognize human IgG via their Fc receptor [37] were incu-
bated with hMOG-DyLight-405 for 2 h in the presence of 
15 µg/ml of the respective IgG preparation. Where indicated, 
Fcγ receptors were blocked using anti-mouse CD16/CD32 
Ab (Clone: 2.4G2, 1:100 dilution).
Assessment of T cell proliferation and differentiation 
in vitro
Adherent BMDM were harvested using cell scraper, 
0.5 × 105 cells/well were plated into 96-well flat-bottom 
plates and pre-stimulated with 50 ng/ml LPS and mMOG in 
the presence of 50 µg/ml 8.18C5 Ab, 8.18C5 F(ab′)2 frag-
ment or isotype control Ab. Where indicated, Fcγ receptors 
were blocked using anti-mouse CD16/CD32 Ab (Clone: 
2.4G2, 1:100 dilution). 24 h thereafter, 1 × 105 MACS-
purified (Pan T cell Isolation Kit, Miltenyi, Bergisch Glad-
bach, Germany) carboxyfluorescein succinimidyl ester 
(CFSE)-stained (CFSE Cell Division Tracker Kit, BioLe-
gend) or unstained T cells from 2D2 mice were added per 
well. 72 h thereafter, T cell proliferation and differentiation 
were evaluated by flow cytometry or ELISA, respectively.
Flow cytometric analysis
To obtain single cell suspensions of lymphoid tissues, 
respective spleens and lymph nodes were carefully dis-
sected and passed through 70 µm strainer. Freshly obtained 
blood was mixed 1:2 with 1 mM EDTA and erythrocytes 
were lysed using BD Pharm Lyse Buffer, according to 
manufacturer’s recommendation. B cells were stained for 
B220 (BioLegend) CD19 (BioLegend) and/or CD20 (Bio-
Legend), T cells for CD3 and/or CD4 (all BD Bioscience). 
T cell activation was determined by expression of CD69 
(BD Bioscience). T cell differentiation was evaluated by 
intracellular cytokine staining for IFN-γ (eBioscience, San 
Diego, USA) and IL-17A (BD Bioscience) after 4-h incu-
bation with phorbol 12-myristate 13-acetate (PMA, 50 ng/
ml) and ionomycin (0.5 μg/ml) in the presence of monensin 
(1 µl Golgi-Stop per ml cell suspension, BD Bioscience). 
Dead cells were excluded using an Aqua Dead Cell Stain 
Kit (Invitrogen, Thermo Fisher Scientific, 405 nm excita-
tion). CNS-infiltrating cells were isolated by discontinuous 
density gradient (Percoll) [24] and stained in a similar man-
ner for CD3, CD4, IFN-γ and IL-17A. Myeloid APC were 
stained for CD11b and CD11c (both BioLegend). Expres-
sion of Fcγ receptor (FcγR) I and III of BMDM and BMDC 
was determined using anti-CD64 Ab (FcγRI, BioLegend) 
and anti-CD16 Ab (FcγRIII, BioLegend). APC secretion of 
IL-1α and IL-23 (both BioLegend) was determined after 5-h 
incubation with 500 ng/ml LPS in the presence of monensin 
(1 µl Golgi-Stop per ml cell suspension. BD Bioscience).
ELISA for cytokine analysis
ELISA for IFN-γ, IL-17 or GM-CSF was performed using 
paired monoclonal Ab per manufacturer’s recommenda-
tions (DuoSet, R&D Systems, Wiesbaden‐Nordstadt, Ger-
many). The results are expressed as an average of dupli-
cates/triplicates ± SEM. iMark microplate reader and 
software was used for data analysis (Bio-Rad Laboratories 
Inc., Hercules, CA, USA).
ELISA for detection of MOG Ab
96-well plates were coated with 10 µg/ml conformational 
mMOG or conformational hMOG in 1xPBS overnight. 
Diluted samples were added for 2 h. After washing, plate-
bound Ab of murine samples and 8.18C5 Ab were detected 
with horseradish peroxidase (HRP)-conjugated anti-mouse 
IgG, directed against the Fc part of the bound Ab (1:6000; 
Sigma-Aldrich) or against the whole molecule (1:5000; 
Sigma-Aldrich). Anti-MOG Ab in human samples were 
detected with HRP-conjugated anti-human IgG (1:1000; 
Sigma-Aldrich). Plates were read at 450 nm wavelength by 
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a Tecan Genios plate reader and analyzed using Magellan6 
software or iMark microplate reader and software.
Histology
Brain and spinal cord tissue was PBS-perfused and cryo-
fixed or perfused and fixed with 4 % paraformaldehyde and 
paraffin embedded. To determine myelin loss and inflam-
matory infiltration, vertically or horizontally oriented 
sections were stained with Luxol Fast Blue and periodic 
acid Schiff (LFB/PAS) or hematoxylin and eosin (H&E), 
respectively. Infiltration of immune cells was determined 
by immunohistochemistry using Ab against CD3 (1:150 
dilution; DCS, Hamburg, Germany), B220 (1:200 dilution; 
BD Pharmingen) or MAC3 (1:200 dilution, BD Biosci-
ence). Evaluation of histologic samples was performed in 
a blinded manner.
Statistical analysis
EAE experiments were evaluated for significance using 
the Mann–Whitney test. The Student t test was used for all 
other statistical comparison. A value of p < 0.05 was con-
sidered significant. Data are presented as mean ± SEM.
Results
Depletion of CD20 positive B cells does not alter 
severity of induced EAE in Th mice nor spontaneous 
EAE development in Thx2D2 mice
To delineate the relative pathogenic contribution of mye-
lin-specific Ab from myelin-specific B cells, we first 
investigated the effect of preventive B cell depletion on 
actively induced EAE in Th mice constitutively contain-
ing a high frequency of MOG-recognizing B cells as 
well as plasma cells producing pathogenic anti-MOG Ab 
(Suppl. Figure 1a). Results were compared to WT mice, 
in which only a comparably small fraction of B cells can 
respond to mouse MOG protein immunization, and devel-
oping Ab titers are non-pathogenic [32]. As shown in 
suppl. Figure 1b, three injections of anti-mouse CD20 Ab 
efficiently depleted virtually all CD20 positive (+) B cells 
from blood, bone marrow, lymph node and spleen of WT 
mice, sparing only CD20 negative B cells in the bone 
marrow. Corresponding results were obtained in second-
ary lymphoid organs of Th mice following anti-CD20 Ab 
treatment (Suppl. Figure 1c). Upon immunization with 
a suboptimal dose of mMOG protein, WT mice devel-
oped mild but consistent EAE with a slight benefit in the 
B cell-depleted group [52]; using the identical induction 
regimen, Th mice developed fulminant EAE irrespective 
of anti-CD20 Ab treatment prior to immunization (Fig. 1a) 
or after EAE onset (Suppl. Figure 1d). These findings were 
closely reflected by a massive CNS demyelination and 
inflammation in both B cell-depleted and isotype-treated 
Th mice (Fig. 1b), along with an unhindered Th1/Th17 dif-
ferentiation in the absence of B cells (Suppl. Figure 1e). 
In line with the fact that anti-CD20 Ab spare CD20 nega-
tive plasma cells, constitutively produced anti-MOG Ab 
remained high in preventatively anti-CD20 Ab treated 
Th mice during the priming- and CNS-infiltration period 
(Fig. 1c).
Next, we applied anti-CD20 Ab treatment to Thx2D2 
mice (Suppl. Figure 1f) containing MOG-recognizing B 
cells, MOG-specific T cells and high titers of constitutively 
produced pathogenic anti-MOG Ab. To our surprise, pre-
ventative B cell depletion at the age of 3–4 weeks neither 
affected incidence of spontaneous EAE (18 anti-CD20-
treated vs. 22 isotype-treated in equally sized groups) nor 
its severity (Fig. 1d). As in immunized Th mice, depletion 
of CD20+ B cells did not affect generation of encephalito-
genic Th1 and Th17 cells (Fig. 1e) nor lower endogenous 
anti-MOG Ab production at the time of disease induction 
(Fig. 1f); analogous clinical and immunological results 
were obtained when anti-CD20 Ab treatment was initiated 
in fully established spontaneous EAE (Suppl. Figure 1g–h).
Transfer of serum from Th mice exacerbates 
experimental autoimmune encephalomyelitis 
in wild‑type mice
These findings endorsed a prominent pathogenic role of 
myelin-reactive Ab independent of B cells, which we 
next investigated directly and independent of anti-CD20 
Ab treatment by adoptive transfer. At first, serum from 
immunized Th mice (Th serum) was transferred into 
MOG p35-55-immunized WT mice. As shown in Fig. 1g, 
repeated intravenous (i.v.) injections of Th serum indeed 
substantially accelerated EAE severity in WT recipients 
and, of note, onset and severity closely resembled EAE in 
immunized Th mice. Histologic analysis revealed accen-
tuated CNS inflammation and demyelination in Th serum 
recipients (Fig. 1h, left and middle), which is in line with 
the reported demyelinating nature of anti-MOG Ab in 
ongoing EAE [26, 46]. Exceeding this anticipated result, 
Th serum recipients furthermore displayed a massive CNS 
infiltration of CD3+ T cells (Fig. 1h, right).
Transfer of anti‑MOG antibodies triggers spontaneous 
experimental autoimmune encephalomyelitis in MOG 
T cell receptor transgenic 2D2 mice
Together with the observation that early B cell depletion 
failed to halt spontaneous EAE development in Thx2D2 
48 Acta Neuropathol (2016) 132:43–58
1 3
Fig. 1  B cells are not required for fulminant induced EAE in Th 
mice nor for spontaneous EAE in Thx2D2. a–c Th or WT mice 
were treated weekly with anti (α)-CD20 or isotype control Ab start-
ing 3 weeks prior to immunization with mMOG. a Mean group EAE 
score ± SEM; n = 10 mice/group; * = p < 0.05 (Mann–Whitney; 
data represent five independent experiments). b CNS inflammatory 
damage at day 48 after immunization. Indicated is the mean group 
score ± SEM of spinal cord inflammation (H&E; left), determined as: 
0 = no inflammation, 1 = slight inflammation. 2 = moderate inflam-
mation, 3 = strong inflammation and the mean % ± SEM of demy-
elinated spinal cord area per group (LFB/PAS; right); n = 3–4 mice/
group; * = p < 0.05 (Mann–Whitney). c Anti-mMOG IgG Ab serum 
levels determined by ELISA (dilution 1:40,500); n = 10 mice/group. 
d–f Thx2D2 mice were treated weekly with anti (α)-CD20 or isotype 
control Ab starting 28 days after birth. d Mean group score and mean 
day of onset of spontaneous EAE in anti (α)-CD20 (n = 18) and iso-
type Ab treated mice (n = 22) ± SEM; p = ns (Mann–Whitney). e 
Frequency of IFN-γ and IL-17A producing T cells isolated from the 
CNS at the end of experiment. f Anti-mMOG IgG Ab determined 
by ELISA (serum dilution 1:13,500); n = 6–16 mice/group. g, h 
EAE was induced in WT mice by immunization with MOG p35-55. 
Arrows indicate i.v. injections of serum containing pathogenic anti-
mMOG Ab (Th serum) or non-pathogenic Ab (control serum). Immu-
nized Th mice not receiving any serum, served as positive control. g 
Mean group EAE score ± SEM; n = 8–10 mice/group; * = p < 0.05 
(WT Th serum recipients vs. WT control; Mann–Whitney; data rep-
resent three independent experiments). h CNS inflammatory dam-
age at day 25 after immunization. Indicated is the mean % ± SEM 
of demyelinated spinal cord white matter area per group (LFB/PAS; 
left), the mean group score ± SEM of inflammation (H&E; middle), 
determined as follows: 0 = no inflammation, 1 = slight inflamma-
tion. 2 = moderate inflammation, 3 = strong inflammation and the 
number of T cells/mm2 spinal cord ± SEM per group determined 
by CD3+ immunostaining (right); n = 4 mice/group; * = p < 0.05 
(Mann–Whitney)
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mice, these findings fueled our hypothesis that in lieu of 
antigen-specific B cells, anti-MOG Ab may be capable 
of triggering activation and expansion of myelin-reactive 
T cells in a manner sufficient to cause EAE. To test this 
hypothesis, we transferred serum from Th mice or puri-
fied 8.18C5 Ab into otherwise naïve 2D2 recipients, which 
contain MOG-specific T cells but no transgenic B cells 
(Fig. 2a). Strikingly, five out of fourteen 2D2 mice receiv-
ing Th serum developed classical EAE with ascending 
paralysis, one mouse developed atypical EAE with severe 
ataxia (Table 1). Histologic analysis confirmed that all 
EAE-diseased Th serum recipients showed extensive CNS 
demyelination, inflammation and infiltration by CD3+ T 
cells (Fig. 2b), while none of the twelve 2D2 mice receiv-
ing control serum showed signs of clinical or histologi-
cal EAE. To confirm that myelin-reactive Ab and not any 
other serum component had triggered EAE, we next trans-
ferred 150 µg of purified 8.18C5 Ab, the amount equivalent 
to its content in 150 µl Th serum. As indicated in Fig. 2c, 
2D2 mice receiving a total of 10 injections showed a rapid 
increase in anti-MOG Ab, comparable to the level observed 
in Thx2D2 mice with spontaneous EAE (gray area). Again, 
thirteen out of twenty-three 8.18C5 Ab recipients, but none 
of the seventeen 2D2 mice receiving control Ab, developed 
severe clinical or histologic EAE (Table 1; Fig. 2d). When 
evaluated by the more sensitive elevated beam test, 8.18C5 
Ab recipients without paralysis yet showed a significant 
decline in their agility (Table 1; Fig. 2e). CNS damage was 
quantified in all 8.18C5 Ab-transferred 2D2 mice, which 
revealed a pronounced inflammation and CNS infiltration 
by both B and T cells in the majority of these mice, while 
extensive demyelination was restricted to the paralyzed 
subgroup (Fig. 2f + g). Here, all histologic parameters 
were in their extent comparable to Thx2D2 mice with spon-
taneous fulminant EAE, while in some cases, the degree of 
infiltration by highly activated MAC3+ macrophages even 
exceeded the level in diseased Thx2D2 mice. To investi-
gate in which sequence peripherally applied anti-MOG Ab, 
MOG-reactive T cells and activated myeloid APC may have 
triggered EAE, we transferred anti-MOG Ab into naïve WT 
mice (Suppl. Figure 2a). Recipients showed no signs of 
paralysis, impaired agility or, importantly, CNS demyeli-
nation (Suppl. Table 1; Suppl. Figure 2b + c), suggesting 
that in the absence of ongoing CNS inflammation, myelin 
within the CNS is not recognized by peripherally applied 
myelin-reactive Ab. Alternatively, myelin-reactive Ab could 
have triggered activation of peripheral myelin-reactive 
T cells prior to CNS entry. To investigate this hypothesis, 
we evaluated proliferation of T cells in lymph nodes and 
spleen of healthy, naïve 2D2 mice after peripheral injec-
tion of 8.18C5 Ab and co-administration of mMOG protein 
intrathecally (Fig. 3a; Suppl. Figure 3a + c). As shown in 
Fig. 3b–d, 8.18C5 Ab triggered in vivo expansion of CD4+ 
T cells in spleen, inguinal and cervical lymph nodes 4 days 
after mMOG injection and 6 days after the initial admin-
istration of 8.18C5 Ab. While at this early time point only 
a trend toward an enhanced Th17 differentiation could be 
observed, administration of 8.18C5 Ab lead to a distinct 
upregulation of the early activation marker CD69 on CD4+ 
T cells (Fig. 3e). Further, co-administration of 8.18C5 Ab 
and mMOG was associated with a concomitant upregu-
lation of MHC class II and an enhanced release of IL-1α 
by CD11b+ myeloid APC (Fig. 3f). To a lesser extent, T 
cell proliferation and activation of myeloid APC were also 
observed in 2D2 mice receiving control Ab, which may 
be reflective of endogenous anti-MOG Ab development in 
these mice when MOG is administered intrathecally. Irre-
spectively, 8.18C5 Ab-mediated in vivo activation and pro-
liferation of T cells as well as activation of myeloid APC 
could be completely abolished by addition of an in vivo 
Fc-blocking Ab (Suppl. Figure 3b; Fig. 3b–f). In conjunc-
tion, these findings indicate that myelin-specific Ab trigger 
activation of peripheral myelin-specific T cells and high-
light Fc-mediated opsonization of antigen as most plausible 
mechanism.  
Anti‑MOG antibodies promote low dose recognition 
of MOG by myeloid antigen‑presenting cells permitting 
activation of MOG‑reactive T cells
Activation of CD4+ T cells requires antigen presentation in 
the context of MHC class II. Prior to its presentation, anti-
gen must be taken up and presented by the immune system, 
which, particularly at low concentrations, can be facili-
tated by specific binding to B cells [9, 17, 38] or Ab [22, 
31]. In the latter case, Ab-decoration triggers Fc receptor-
mediated internalization and processing of the antigen by 
APC [49], followed by its presentation to adaptive immune 
cells. This mechanism of Ab-mediated antigen opsoniza-
tion is believed to be central for instance in development 
of systemic lupus erythematosus (SLE) [15]. To investigate 
whether in our setting, MOG-specific Ab may have trig-
gered in vivo activation of myelin-specific T cells [35] by 
opsonization of rare CNS auto-antigen, we developed an 
in vitro setting capable of dissecting the respective com-
ponents; we generated BMDM or BMDC from WT mice 
expressing high levels of Fc receptors or from knockout 
mice lacking Fcγ receptors (FcγR−/−) (Fig. 4a + b). Fur-
ther, we digested the 8.18C5 Ab to obtain an antigen-rec-
ognizing, but Fc-cleaved F(ab′)2 fragment (Fig. 4c; Suppl. 
Figure 4a + b). Using these tools, we demonstrated that 
intact 8.18C5 Ab strongly promoted recognition and inter-
nalization of fluorescence-labeled mMOG by either BMDC 
or BMDM (Fig. 4d + e, left). This effect strictly depended 
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on cellular expression of Fcγ receptors (Fig. 4e, right); 
along the same lines, the Fc-cleaved 8.18C5 F(ab′)2 frag-
ment failed to enhance internalization and rather neutral-
ized antigen recognition (Fig. 4f). Of interest, Ab-mediated 
opsonization similarly occurred when the random control 
antigen OVA was used in combination with anti-OVA 
Ab (Fig. 4g), corroborating that Ab opsonize any fitting 
antigen.
To understand the downstream immunological con-
sequences of Ab-mediated antigen opsonization we 
co-cultured WT BMDM with naïve 2D2 T cells, again 
in the presence of mMOG. In line with our in vivo find-
ings, addition of 8.18C5 Ab specifically accelerated T cell 
proliferation and differentiation into encephalitogenic T 
cells, while blockade of Fcγ receptors on APC reversed 
this effect (Fig. 5a–c; Suppl. Figure 4c). Along the same 
lines, the 8.18C5 F(ab′)2 fragment again failed to enhance 
internalization and subsequent presentation of mMOG to 
myelin-specific T cells (Fig. 5d). In summary, these results 
indicate that in development of CNS autoimmune disease, 
systemic auto-Ab facilitate APC recognition of otherwise 
undetected CNS antigen, resulting in activation, pro-
inflammatory differentiation and CNS infiltration of auto-
reactive T cells.
Fig. 2  Transfer of anti-mMOG Ab containing serum or purified anti-
mMOG Ab triggers spontaneous EAE in 2D2 recipients. a Overview 
of experimental setup. b Naïve 2D2 mice received i.v. injections of 
Th serum or control serum. CNS inflammatory damage determined 
at day 18 after EAE onset. Indicated is the mean % ± SEM of 
demyelinated spinal cord area per group (LFB/PAS; left), the mean 
group score ± SEM of spinal cord inflammation (H&E; middle), 
determined as follows: 0 = no inflammation, 1 = slight inflamma-
tion. 2 = moderate inflammation, 3 = strong inflammation and the 
number of T cells/mm2 spinal cord ± SEM per group determined by 
CD3+ immunostaining (right); n = 2 mice/group. c–g Naïve 2D2 
mice received i.v. injections of 8.18C5 or isotype control Ab. c Anti-
mMOG Ab serum levels in recipients determined by ELISA (dilution 
1:13,500). Arrows indicate injections of 8.18C5 or isotype control 
Ab. Gray area represents the range of anti-mMOG Ab predetermined 
in spontaneously EAE-diseased Thx2D2 mice; n = 5 mice/group. d 
Individual EAE courses of 2D2 mice receiving 8.18C5 Ab. e Elevated 
beam test of 2D2 mice receiving 8.18C5 or isotype control Ab. Indi-
cated is the mean time in seconds (sec.) per group ± SEM required to 
traverse the beam; n = 4–5 mice/group; * = p < 0.05 (Mann–Whit-
ney). f Demyelination (LFB/PAS), overall inflammation (H&E) and 
immune cell infiltration of the spinal cord evaluated by CD3-, B220- 
and MAC3-immunohistochemistry 40 days after first Ab transfer. 
Representative sections (right) and group mean % ± SEM of demy-
elinated white matter area, number of inflammatory spots per spinal 
cord section (inflammatory index) and of infiltrating immune cells/
mm2 spinal cord (left). Mice with paralysis in purple; for comparison, 
Thx2D2 mice with EAE are depicted. Scale bar overview = 500 µm, 
scale bar inlay = 50 µm; n = 12–23 mice/group; * = p < 0.05 
(Mann–Whitney). g CD3 immunostaining of T cells in the brain at 
day 40 after first transfer. Representative sections (right) and abso-
lute number of infiltrating T cells/section (left). Mice with paralysis 
in purple; for comparison Thx2D2 mice with EAE are depicted. Scale 
bar overview = 1000 µm, scale bar inlay = 100 µm; n = 4–12 mice/
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Fig. 3  Transfer of anti-mMOG 
Ab into 2D2 mice triggers 
in vivo activation and expansion 
of peripheral myelin-reactive T 
cells in an Fc-dependent man-
ner. a Overview of experimental 
setup. a–f Naïve 2D2 mice were 
treated daily with Fc receptor 
blocking anti-CD16/CD32 or 
control Ab i.p. during the entire 
experiment. Starting at day (d)3, 
mice received three consecu-
tive i.v. injections of 8.18C5 
or control Ab. mMOG was 
injected intrathecally at d5. 24 h 
before evaluation, mice received 
BrdU i.p. (d8). In vivo prolifera-
tion of CD4+ T cells (pre-gated 
on viable CD4+ cells) analyzed 
by BrdU uptake in b spleen, c 
inguinal lymph nodes (iLN) and 
d cervical lymph nodes (cLN). 
b–d Representative FACS 
plots (left) and frequency of 
BrdU+ CD4+ cells in % ± SEM 
(right); n = 5–10 mice/group; 
* = p < 0.05 (t test). e Expres-
sion of CD69 (mean fluores-
cence intensity; MFI) and % of 
IL-17A and IFN-γ producing 
CD4+ cells ± SEM isolated 
from cLN (pre-gated on intact 
cells). f Expression of MHC 
class II (MHCII; MFI) and % 
of IL-1α and IL-23 producing 
CD11b+ cells ± SEM isolated 
from cLN (pre-gated on intact 
cells)
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Fig. 4  Opsonization of 
conformational mMOG by 
anti-mMOG Ab fosters Fc-
mediated antigen uptake. Mean 
expression of Fcγ receptor 
(FcγR)I and FcγRIII by a WT 
BMDC and b WT or FcγR−/− 
BMDM. c Competitive binding 
of 8.18C5 F(ab′)2 and intact 
8.18C5 Ab at various ratios 
to mMOG; plate-bound Ab 
detected by anti-mouse IgG Ab 
against the Fc part. d–f Phago-
cytosis of mMOG-DyLight-405 
by APC. APC were incubated 
with mMOG-DyLight-405 
in the presence of 8.18C5, or 
isotype control Ab (mean % of 
mMOG-DyLight-405 posi-
tive (mMOG+) APC ± SEM, 
gated on intact CD11b+/
CD11c+ cells). d Phagocytosis 
of mMOG by WT BMDC. 
Representative data set shown; 
combined statistical analysis 
of two independent experi-
ments: p < 0.05 for 8.18C5 vs. 
isotype Ab at 0.5 and 1 μg/
ml mMOG (t test). e Phagocy-
tosis of mMOG by WT (left) 
or FcγR−/− (right) BMDM. 
Representative data set shown; 
combined statistical analysis of 
two independent experiments: 
p < 0.05 for 8.18C5 vs. isotype 
control Ab at 0.5, 1 and 5 μg/
ml mMOG of WT BMDM (t 
test). f Phagocytosis of mMOG 
by WT BMDM, additionally in 
the presence of 8.18C5 F(ab′)2 
fragments. Representative data 
set shown; combined statisti-
cal analysis of two independ-
ent experiments: p < 0.05 for 
8.18C5 Ab vs. 8.18C5 F(ab′)2 
at 0.5 and 5 μg/ml mMOG (t 
test). g Phagocytosis of OVA-
FITC by BMDM. BMDM were 
incubated with OVA-FITC in 
the presence of anti-OVA Ab 
or isotype control Ab (mean 
% of OVA-FITC positive 
(OVA+) BMDM, gated on 
intact CD11b+/CD11c+ cells). 
Representative data set shown; 
combined statistical analysis of 
two independent experiments: 
p < 0.05 for anti-OVA vs. 
isotype control Ab at 0.05 and 
0.1 μg/ml OVA (t test)
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Patient‑derived anti‑MOG antibodies mediate 
opsonization of human MOG protein
To exemplify that human IgG is capable of opsonizing 
human myelin protein, we next investigated IgG prepara-
tions obtained from two NMOSD patients with high titers of 
anti-MOG Ab determined in an established cell-based assay 
[30]. As a prerequisite to be tested in our in vitro assay, we 
first ensured that patient-derived anti-MOG Ab recognized 
soluble hMOG in vitro by a conventional ELISA (Fig. 6a). 
Applying the IgG preparations to our phagocytosis assay, 
we indeed observed that both anti-MOG Ab containing 
IgG preparations significantly enhanced the APC uptake of 
hMOG, when compared to an anti-MOG Ab negative IgG 
preparation obtained from a healthy individual (Fig. 6b). 
Ab-mediated opsonization could be largely reversed by 
addition of an Fc receptor blocking Ab (Fig. 6c), mecha-
nistically corroborating that under these conditions human 
anti-MOG Ab facilitate APC uptake of human CNS antigen 
in an Fc-dependent manner.
Fig. 5  Opsonization-triggered antigen uptake results in an increased 
capability of myeloid APC to generate encephalitogenic T cells. a–d 
WT BMDM co-cultured with CFSE-labeled MOG-specific 2D2 T 
cells in the presence of mMOG. a Proliferation of CD4+ T cells in 
the presence of 8.18C5 or isotype control Ab determined by CFSE 
dilution (representative FACS plot, left; mean % of proliferating T 
cells in duplicates ± SEM, right). Representative data set shown; 
combined statistical analysis of four independent experiments: 
p < 0.05 for 8.18C5 vs. isotype control Ab at 0.1 μg/ml mMOG 
(t test). b Differentiation of naïve T cells into Th1-, Th17- or GM-
CSF-producing T cells determined by production of IFN-γ, IL-17 
or GM-CSF in the presence of 8.18C5 or isotype control Ab (dupli-
cates ± SEM). c Proliferation of CD4+ T cells in the presence of 
8.18C5 Ab or a combination of 8.18C5 Ab and Fcγ receptor block-
ing anti-CD16/CD32 Ab (8.18C5 + Fc-block) determined by CFSE 
dilution (mean % of proliferating T cells in duplicates ± SEM). Rep-
resentative data set shown; combined statistical analysis of two inde-
pendent experiments: p < 0.05 for 8.18C5 Ab vs. 8.18C5 F(ab′)2 at 
1 μg/ml mMOG and p = 0.054 at 10 µg/ml mMOG (t test). d Prolif-
eration of CD4+ T cells in the presence of 8.18C5 Ab or the 8.18C5 
F(ab′)2 fragment determined by CFSE dilution (mean % of proliferat-
ing T cells in duplicates ± SEM)
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Discussion
Antigen-specific B cells are increasingly recognized to act as 
important APC in models of human CNS demyelinating dis-
eases. High affinity BCR binding of antigen triggers B cell 
activation and enables subsequent presentation of processed 
antigen to T cells. Thus, when B cells and T cells share anti-
gen recognition, B cells are the dominant APC population 
and mere co-existence of antigen-specific B and T cells can 
prompt spontaneous CNS autoimmune disease [3, 21, 39]. 
A recent publication demonstrated that in this setting, spon-
taneous EAE can occur without the requirement of myelin-
specific Ab [34]. Here, we investigated the inverse scenario, 
and report that in the absence of antigen-specific B cells, 
myelin-specific Ab in conjunction with T cells recognizing 
MOG suffice to trigger spontaneous EAE. At first sight, these 
two reports on the relevance of B cells versus myelin-spe-
cific Ab appear conflicting; upon closer view though, the link 
between both observations is specific recognition of endog-
enously rare antigen, which can be achieved by two distinct, 
yet related mechanisms: by binding to the BCR of B cells 
or alternatively to the corresponding Ab, which permits Fc-
mediated antigen recognition by myeloid APC. Both mecha-
nisms result in antigen uptake, processing and presentation 
by B cells or myeloid APC, respectively. This concept is sup-
ported by several mechanistic observations; in Thx2D2 mice, 
very low concentrations of mMOG added to a single cell 
suspension of purified splenocytes stimulated T cell prolif-
eration [3, 21], while this effect was abolished when B cells 
were removed. Correspondingly, in our study, the addition of 
MOG-specific Ab enabled myeloid APC to recognize anti-
gen at very low concentrations in an Fc-dependent manner 
and to activate co-cultured T cells. Antigen-specific B cells 
and antigen-specific Ab may thus independently contribute 
to the risk to develop CNS autoimmune disease, while the 
common element of disease initiation is specific recognition 
of rare CNS antigen subsequently boosting a disease-driving 
auto-reactive T cell response.
In line with this concept, we could show that anti-CD20 
Ab-mediated depletion of myelin-specific B cells did not 
affect development of encephalitogenic T cells and failed to 
prevent or ameliorate EAE in the presence of endogenously 
produced myelin-specific Ab. Transfer of serum obtained 
from Th mice containing high levels of anti-MOG Ab exac-
erbated EAE in WT recipients in an extent indistinguish-
able from the fulminant course in Th mice containing both 
myelin-specific Ab and B cells. Furthermore, Th serum or 
purified anti-MOG Ab triggered spontaneous EAE in naïve 
2D2 recipients. In conjunction, these findings evidently 
Fig. 6  IgG isolated from patients with NMOSD facilitate recogni-
tion of hMOG protein. a Detection of Ab against hMOG in a purified 
IgG fraction of a patient with NMOSD (α-MOG pos. IgG) by ELISA. 
Plate-bound Ab were detected with anti-human IgG Ab directed 
against the Fc part. For ELISA, intravenous IgG (control IgG) 
served as negative control. b Phagocytosis of hMOG-DyLight-405 
by WT BMDM. Cells were incubated with hMOG-DyLight-405 
in the presence of IgG samples from NMOSD patients containing 
anti-MOG Ab (α-MOG pos. IgG #1 and #2) or an anti (α)-MOG Ab 
negative (neg.) IgG preparation from a healthy individual (mean % 
of hMOG-DyLight-405 positive (hMOG+) APC, gated on intact 
CD11b+/CD11c+ cells). Representative data set shown; p < 0.05 
for α-MOG pos. IgG #1 vs. α-MOG neg. IgG and α-MOG pos. IgG 
#2 vs. α-MOG neg. IgG at 5 µg/ml hMOG (t test). c Phagocytosis 
of hMOG-DyLight-405 by WT BMDM. Cells were incubated with 
hMOG-DyLight-405 in the presence of anti-MOG positive IgG #2 or 
a combination of anti-MOG positive IgG #2 and Fcγ receptor block-
ing anti-CD16/CD32 Ab (8.18C5 + Fc-block; mean % of hMOG+ 
APC, gated on intact CD11b+/CD11c+ cells)
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support a crucial role of myelin-specific Ab independent 
of myelin-specific B cells, which is further corroborated by 
the observation that in the absence of an immediate clini-
cal benefit, Th mice receiving anti-CD20 Ab either in pre-
vention or reversal showed a slight amelioration late in the 
chronic course of EAE, when levels of myelin-specific Ab 
declined (Fig. 1a + c; Suppl. Figure 1d). It is unclear and 
rightful to question whether in patients with MS, endoge-
nous self-reactive Ab titers can reach corresponding func-
tional relevance. Nevertheless, it could be important to rec-
ognize the general concept that Ab-mediated opsonization 
can functionally bypass antigen-specific B cells and that 
this alternative pathway of self-antigen recognition is not 
targeted and likely not affected by the soon to be approved 
MS treatment of anti-CD20 Ab. Accordingly, Ab-mediated 
antigen recognition by myeloid APC may become particu-
larly important when antigen-specific B cells are extin-
guished, a notion to be kept in mind when individuals fail 
to respond to anti-CD20 Ab treatment [2, 7].
One central and widely unanswered question in the 
pathogenesis of CNS autoimmune disease remains where 
and how CNS antigens are initially recognized. In the 
absence of ongoing inflammation, the CNS is a well-pro-
tected, immune-privileged site and molecularly large Ab 
should not be capable of crossing the intact blood–brain 
barrier in a meaningful manner. Therefore, it is rather 
unlikely that peripherally administered myelin-reactive Ab 
can recognize and possibly degrade intact myelin within 
the otherwise healthy CNS. One of our control settings, in 
which anti-MOG Ab were transferred into naïve WT mice, 
consolidates this notion as despite intensive investigation, 
no CNS damage was observed. Alternatively, a plausible 
site of initial recognition of CNS antigen is cervical lymph 
nodes [10, 40], where vessels drain brain interstitial fluid 
[1, 28]. Supporting this concept, traces of myelin have 
been detected in CNS draining deep cervical lymph nodes 
of patients with MS [13]. A paralleling observation was 
reported in EAE-diseased mice [53], and surgical excision 
of cervical lymph nodes reduced relapse severity in chronic 
EAE [50]. To corroborate this possible path of CNS drain-
age we first injected 10 % Evans blue intrathecally and 
indeed retrieved the blue dye 1 h after its injection from 
cervical lymph nodes (suppl. Figure 3c). We next applied 
MOG protein intrathecally and in addition injected 8.18C5 
Ab peripherally into healthy, naïve 2D2 recipients. Four 
days after MOG injection and 6 days after initial applica-
tion of anti-MOG Ab, this regimen caused a marked in vivo 
expansion of CD4+ T cells in lymph nodes and spleen of 
otherwise healthy mice. In conjunction, these data point 
toward peripheral lymphoid organs as the most plausible 
site where CNS-reactive Ab facilitated initial recognition of 
CNS-drained antigen, which subsequently triggered devel-
opment of an encephalitogenic T cell response.
Using human IgG preparations in our in vitro setting was 
meant to exemplify that peripherally produced human anti-
CNS Ab are generally capable of opsonizing human CNS 
antigen. To date, it remains unknown whether this effect 
occurs in patients with CNS demyelinating disorders in a 
functionally meaningful manner, although early develop-
ment of anti-MOG Ab in MS [23] as well as the pronounced 
peripheral production of Ab against AQP-4 or MOG in 
NMO and NMOSD patients [20] highlights this possibil-
ity. Ab-decoration of auto-antigen is indeed known to occur 
in a variety of paraneoplastic disorders [44] and to enhance 
severity of systemic autoimmune conditions, such as SLE 
[42, 47]. In its pathogenesis, Ab directed against nuclear anti-
gens are believed to opsonize apoptotic cells enhancing their 
uptake by dendritic cells [14], which in return may augment 
an autoimmune T cell response [15]. Further paralleling our 
findings in patients in an intriguing manner, serum from SLE 
patients specifically enhanced in vitro phagocytosis of apop-
totic Jurkat cells by normal healthy donor macrophages [45]. 
The clinical relevance of this effect is further supported by 
the observation that the effectiveness of anti-CD20 Ab treat-
ment negatively correlates with an expanded auto-Ab profile 
in patients with SLE [6]. Besides inducing or promoting auto-
immunity, the general concept of Ab-mediated opsonization 
can also be applied therapeutically, when monoclonal Ab 
are used to alert the immune system to tumor cells enhanc-
ing cell-mediated cytotoxicity [43] as well as priming of an 
adaptive immune response [48]. Lastly, immunotherapy via 
Ab-mediated opsonization is currently pioneered to target 
pathological protein deposits in treatment of neurodegenera-
tive disorders [5, 33]. In summary, Ab-mediated opsonization 
widely occurs in development and progression of systemic 
autoimmune conditions and is therapeutically harnessed to 
enhance clearance of potentially harmful antigen.
To date, the role of self-reactive Ab in MS has been 
primarily projected into enhancing CNS demyelination 
in ongoing acute disease flares [16], while in NMO, anti-
AQP-4 Ab are believed to selectively target astrocytes, fol-
lowed by severe secondary demyelination [29]. Our find-
ings reported here extend this view and suggest that in 
addition, CNS-reactive Ab may be crucial for initiating and 
amplifying an adaptive autoimmune response to traces of 
otherwise unrecognized CNS auto-antigen. This novel con-
cept has several important implications: first, while CNS-
reactive Ab may initiate this chain of events, they require 
responding T cells to hereby cause harm. This may explain 
why myelin-specific Ab can also be found in controls and 
healthy volunteers, which do not develop CNS demyelina-
tion [23]. Second, in the context of MS, a serum auto-Ab 
response, particularly against MOG, widely occurs at early 
disease stages and in children with MS [11, 23]. In light of 
our new findings and opposite to our current understanding, 
this humoral response could be tremendously important for 
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initial activation of myelin-specific T cells as well as for 
development of first clinical relapses, when the availability 
of CNS auto-antigen is still limited. Third and most impor-
tantly, our data implicate that independent of current B cell-
oriented therapeutic approaches, inhibiting or modulating 
the auto-reactive humoral response or interfering with its 
downstream signaling may be of enormous, vastly unrecog-
nized therapeutic potential for prevention of early relapses 
and disease progression in MS, NMO and related disorders.
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